Profile picture

Doctor Rene Rettl

Medical University of Vienna, Vienna (Austria)
Membership: FESC Member
Follow
Logo ESC

Contributor content

DPD quantification correlates with ECV and disease severity in patients with ATTR-CM
Presentation
DPD quantification correlates with ECV and disease severity in patients with ATTR-CM
DPD quantification correlates with ECV and disease severity in  transthyretin cardiac amyloidosis
Presentation
DPD quantification correlates with ECV and disease severity in transthyretin cardiac amyloidosis
Novel SPECT/CT biomarker in transthyretin cardiac amyloidosis: correlation with myocardial amyloid load and cardiac structure and function
Presentation
Novel SPECT/CT biomarker in transthyretin cardiac amyloidosis: correlation with myocardial amyloid load and cardiac structure and function
Monitoring patisiran and inotersen treatment with quantitative SPECT/CT in hereditary transthyretin amyloid cardiomyopathy
Presentation
Monitoring patisiran and inotersen treatment with quantitative SPECT/CT in hereditary transthyretin amyloid cardiomyopathy
Two-dimensional speckle-tracking echocardiography  in tafamidis-treated patients with transthyretin amyloid cardiomyopathy: a glimmer of hope for viable therapy monitoring?
Presentation
Two-dimensional speckle-tracking echocardiography in tafamidis-treated patients with transthyretin amyloid cardiomyopathy: a glimmer of hope for viable therapy monitoring?
Cardiac imaging in tafamidis-treatment patients with transthyretin amyloid cardiomyopathy
Presentation
Cardiac imaging in tafamidis-treatment patients with transthyretin amyloid cardiomyopathy
Quantification of  myocardial amyloid deposition in tafamidis-treated patients with transthyretin amyloid cardiomyopathy
Presentation
Quantification of myocardial amyloid deposition in tafamidis-treated patients with transthyretin amyloid cardiomyopathy
Effects of tafamidis on quantification of myocardial amyloid deposits in patients with transthyretin amyloid cardiomyopathy
Presentation
Effects of tafamidis on quantification of myocardial amyloid deposits in patients with transthyretin amyloid cardiomyopathy
Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy
Presentation
Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy
Effects of tafamidis on exercise capacity, cardiac function and myocardial amyloid deposition in patients with transthyretin amyloid cardiomyopathy
Presentation
Effects of tafamidis on exercise capacity, cardiac function and myocardial amyloid deposition in patients with transthyretin amyloid cardiomyopathy

ESC 365 is supported by